Veracyte, Inc.

Today, we announced third-quarter 2026 financial results, reflecting continued momentum across our #CancerDiagnostics portfolio:

🔹 $151.8 million in total revenue, up 15% year over year

🔹 $146.4 million in testing revenue, up 15% year over year

🔹 $41.2 million in adjusted EBITDA, representing 27.2% of revenue

| Q3 Highlights |

🔹 Acquired Convergent Genomics, Inc., expanding our urology portfolio with a urinary tumor DNA testing platform to help guide bladder cancer care across the patient journey.

🔹 Secured Medicare reimbursement for the Prosigna® Breast Risk of Recurrence (ROR) test in the U.S. for eligible patients* with early-stage HR+ breast cancer.

🔹 Surpassed more than 1 million patients served with our high-performing molecular tests.

| Resources |

🔹 View #Q3Earnings Presentation - investor.veracyte.com/static-files/3…

🔹 Explore our technology and pipeline - veracyte.com/innovation/tec…

🔹 Learn about some of our active clinical studies - veracyte.com/innovation/cli…

#Veracyte #InvestorRelations $VCYT #PrecisionMedicine

| Notes |

* Prosigna testing is available in the United States as a laboratory developed test (LDT) service and has not been cleared or approved by the FDA. The test is not yet available in New York.

** This article contains forward-looking statements, which involve risks and uncertainties. For more information visit - veracyte.com/cautionary-not…

10 abstracts involving our Afirma® Genomic Sequencing Classifier test and the Veracyte Genomic Resource for Intelligent Discovery (GRID), a research-use-only database, will be presented at the 2026 Annual Meeting of the American Thyroid Association (#ATA2026) in Philadelphia from November 4–7, 2026.

The presentations explore how gene expression can provide insights beyond individual genetic alterations to inform #ThyroidNodule diagnosis and assessment of cancer aggressiveness. Together, the studies build on Afirma’s long-established role in thyroid nodule diagnosis and explore how gene expression data can help researchers answer additional questions about cancer risk and biology.

Visit Booth #6 to connect with our team and learn more about the #AfirmaThyroid test.

| Key Presentation Highlights |

🔹 Oral presentations from Johns Hopkins and MD Anderson will examine potential imaging and treatment targets.

🔹 Posters include studies using the Veracyte GRID research-use-only database to investigate preoperative diagnosis and recurrence risk.

🔹 Additional posters will discuss independent research on molecular testing and long-term outcomes.

| Resources |

🔗 Read the full press release - investor.veracyte.com/news-releases/…

🔗 Event information -  veracyte.com/company/event/…

🔗 Afirma GSC - veracyte.com/tests/afirma-t…

#RealWorldEvidence #ThyroidHealth #ThyroidCare #AfirmaThyroid #TeamVeracyte

Note: This article contains forward-looking statements, which involve risks and uncertainties. For more info visit -
veracyte.com/legal/cautiona…

#ESMO26 is a wrap! Here are a few key moments (and some thank-yous) from the Veracyte team.

🔹 #STAMPEDE: Huge thank you to Dr. Sarah Howlett, M. B.B. S. of University College London (@ucl) for presenting results from a combination analysis of STAMPEDE and real-world datasets. Dr. Howlett shared that her findings show that the Decipher® Prostate test can predict benefit from adding abiraterone to androgen deprivation therapy in men with node-negative clinically very high-risk hashtag#ProstateCancer.

🔹 #OPTIMA: We are also grateful to Peter Hall, M.B.Ch.B., M.R.C.P., Ph.D. from the University of Edinburgh for providing an economic analysis of the OPTIMA trial to explore the impact of chemotherapy decisions for HR+ early breast cancer patients, informed by the Prosigna® Breast ROR test. In the talk, Dr. Hall discussed how Prosigna test-directed chemotherapy lowered care costs and increased quality-adjusted life-years (QALYs) for patients. Combined with previous OPTIMA results showing that Prosigna test-directed treatment was non-inferior for 5-year invasive breast cancer-free survival, these data support wider adoption of the Prosigna Breast test in #BreastCancer care.*

🔹 IINTerpath-001: Georgina V. Long, PhD, MBBS, FRACP shared the first results from the Phase 3 INTerpath-001 trial, which showed that adding  intismeran autogene, an investigational mRNA vaccine tailored to the mutations in each patient’s tumor, to pembrolizumab reduced the risk of melanoma recurrence or death by 42% compared with pembrolizumab alone after surgery. While this isn’t Veracyte news, it’s a monumental moment for the #PrecisionOncology community and the first positive Phase 3 result for an mRNA cancer vaccines as a burgeoning modality. Although still early, seeing molecular insights from a patient’s own tumor shape treatment and improve outcomes is worth celebrating!

🔹 We'd also like to thank Alice Bernard-Tessier, M.D., Michela Piacentini, M.D., Melvin L.K. Chua, M.B.B.S., F.R.C.R., Ph.D., and Chiara Mercinelli, M.D. for presenting additional Decipher Urologic data, and all investigators, site teams, and participants who made this research possible.

🔗 To see where #TeamVeracyte is headed next, visit our upcoming events page - veracyte.com/company/events…

#MedicalOncology #RWD #DecipherUrologicCancers #Prosigna

| Notes |

*Prosigna testing is available in the US as a laboratory developed test (LDT) service and has not been cleared or approved by the FDA. The test is not yet available in New York. The Prosigna Breast Cancer Prognostic Gene Signature Assay is available as an IVD test in territories where registered.

**This article contains forward-looking statements, which involve risks and uncertainties.

Join us at the 2026 American Thyroid Association Annual Meeting (#ATA2026) in Philadelphia from November 4th to November 7th!

Visit Booth #6 to connect with our team and learn how the market-leading* Afirma® Genomic Sequencing Classifier test combines transcriptome-wide analysis with real-world clinical evidence to help advance thyroid nodule care.

During the meeting, be sure to:

✅ Visit our professional headshot booth, open during exhibit hall hours
✅ Attend our sponsored product theater (see details below)
✅ Meet with our team to discuss the latest evidence supporting Afirma
✅ Explore the latest Afirma data by attending featured oral and poster presentations

| Product Theater Details |

📌 Title: The Afirma® GRID™ Research Tool Helps Drive Discovery for Future Patients
🎤 Presenters: Dr. Gustavo Romero-Velez (Cleveland Clinic), Dr. Arti Bhan (Henry Ford Health), Adeeb Ansari, MD (Director Medical Science Liaison, Veracyte)
📅 Date / Time: Thursday, November 5th at 10:25 AM–11:25 AM (EDT)
📍 Location: Expo Theater (Exhibit Hall)

| Key Oral Presentations |

📌 Title: mRNA Analysis of Cell-Surface Protein Targets in Medullary Thyroid Cancer Fine Needle Aspiration Samples
🎤 Presenter: Sarah Hamidi, M.D. (MD Anderson Cancer Center)
📅 Date/time: Thursday, November 5th, 5:30 PM - 5:45 PM (EDT)
📍 Location: Floor 5, Salon H

📌 Title: Prostate-Specific Membrane Antigen (PSMA) mRNA Expression in Thyroid FNA Samples with Bethesda III-VI Cytology Predicts Lymphatic and Angioinvasion in Surgically Resected Tumors
🎤 Presenter: Wassim Najjar, M.D. (John Hopkins University) and Prasanna Santhanam, MD (Johns Hopkins University)
📅 Date/time: Friday, November 6h, 5:30 PM - 5:45 PM (EDT)
📍 Location: Floor 5, Salon H

| Resources |

🔗 Event information: veracyte.com/company/event/…

📄 Download the Afirma 2025 Research Collection: veracyte.com/afirma-2025-re…

*Based on claims for CPT codes 81546, 0026U, 0245U as of 8/12/2026 – found at: data.cms.gov

#RealWorldEvidence #ThyroidNodules #ThyroidHealth #ThyroidCare #AfirmaThyroid #TeamVeracyte

Note: This article contains forward-looking statements, which involve risks and uncertainties. veracyte.com/cautionary-not…

We will report financial results for the third quarter of 2026 on November 4, 2026 at 4:30 PM ET. Join our conference call and webcast to learn more about the financial results and receive a general business update.

| Resources |

🔗 Access the live audio webcast here - investor.veracyte.com/events-present…

📄 Read the full announcement - investor.veracyte.com/news-releases/…

#Q3Earnings #FinancialResults #InvestorRelations #Biotech #Diagnostics $VCYT #CancerDiagnostics #PrecisionMedicine

Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information visit - veracyte.com/cautionary-not…